News2 mins ago
MEDSIR’s PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
MEDSIR PHERGain trial is the first to use an adaptive design in HER2-positive early breast cancer. Tweet this PHERGain is a randomized, controlled phase 2 clinical...
